An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3630-3636

  Davis, Ian D ^a,c,e   Skrumsager, Birte K ^d   Cebon, Jonathan ^a,c   Nicholaou, Theo ^a,c   Barlow, John W ^c   Moller, Niels Peter Hundahl ^d   Skak, Kresten ^d   Lundsgaard, Dorthe ^d   Frederiksen, Klaus Stensgaard ^d   Thygesen, Peter ^d   McArthur, Grant A ^b,c  

^a AUSTIN HEALTH   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c Cancer Trials Australia   (Australia)

^d NOVO NORDISK A S   (Denmark)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE ANTIBODY; GRANZYME B; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 21; INTERLEUKIN 21 ANTIBODY; MESSENGER RNA; PERFORIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINEPHOSPHATE; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOLOGY; BLOOD; CANCER PATIENT; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERURICEMIA; HYPOFIBRINOGENEMIA; HYPONATREMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; RASH; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR VOLUME; UPREGULATION; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANZYMES; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; PORE FORMING CYTOTOXIC PROTEINS; RECOMBINANT PROTEINS;

EID: 34250761481     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0410     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005;365:687-701.
3. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-34.
4. Balch CM, Buzaid AC, Soong S-J, et al. Final version of the American Joint Committee on cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
5. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000;6 Suppl 1:S11-4.
6. Atkins MB, Regan M, McDermott D. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 2004;10:6342S-6S.
7. Eton O, Legha SS, Bedikian AY, et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002;20:2045-52.
8. Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000;408:57-63.
9. Asano R, Kudo T, Makabe K, Tsumoto K, Kumagai I. Antitumor activity of interleukin-21 prepared by novel refolding procedure from inclusion bodies expressed in Escherichia coli. FEBS Lett 2002;528:70-6.
10. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common γ-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001;167:1-5.
11. Brenne AT, Ro TB, Waage A, Sundan A, Borset M, Hjorth-Hansen H. Interleukin-21 is a growth and survival factor for human myeloma cells. Blood 2002;99:3756-62.
12. Parrish-Novak J, Foster DC, Holly RD, Clegg CH. Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 2002;72:856-63.
13. + T cell expansion and function. J Exp Med 2005;201:139-48.
14. Li Y, Bleakley M, Yee C. IL-21 Influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005;175:2261-9.
15. Suto A, Nakajima H, Hirose K, et al. Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Cε transcription of IL-4-stimulated B cells. Blood 2002;100:4565-73.
16. Ma H-L, Whitters MJ, Konz RF, et al. IL-21 Activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-γ. J Immunol 2003;171:608-15.
17. Wang G, Tschoi M, Spolski R, et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res 2003;63:9016-22.
18. Ugai S, Shimozato O, Yu L, et al. Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects. Cancer Gene Ther 2003;10:771-8.
19. Ugai S, Shimozato O, Kawamura K, et al. Expression of the interleukin-21 gene in murine colon carcinoma cells generates systemic immunity in the inoculated hosts. Cancer Gene Ther 2003;10:187-92.
20. Di Carlo E, Comes A, Orengo AM, et al. IL-21 induces tumor rejection by specific CTL and IFN-γ-dependent CXC chemokines in syngeneic mice. J Immunol 2004;172:1540-7.
21. + T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol 2004;173:900-9.
22. Curti BD. Immunomodulatory and antitumor effects of interleukin-21 in patients with renal cell carcinoma. Expert Rev Anticancer Ther 2006;6:905-9.
23. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 Induces the functional maturation of murine NK cells. J Immunol 2004;172:2048-58.
24. Roda JM, Parihar R, Lehman A, Mani A, Tridandapani S, Carson WE III. Interleukin-21 enhances NK cell activation in response to antibody-coated targets. J Immunol 2006;177:120-9.
25. Hughes SD, Ponce RA, Krejsa C, et al. IL-21 Improves rituximab-mediated B cell depletion. Blood 2005;106:345.
26. Hughes SD, Krejsa C, Wagner F, et al. IL-21 enhancement of rituximab-mediated B cell depletion. J Clin Oncol 2005;16 Suppl 1:182S.
27. McArthur G, Cebon J, Skrumsager BK, Skak K, Davis ID. Phase 1 dose-escalation study of recombinant human Interleukin-21 (IL-21) in patients with metastatic melanoma: preliminary results of tolerability and effect on immune response biomarkers. The European Cancer Conference (ECCO); 2005; Paris. p. 531.
28. Davis ID, McArthur G, Frederiksen KS, Lundsgaard D, Skak K, Skrumsager BK. Recombinant human interleukin-21 (IL-21) is well tolerated and can mediate biological effects in patients with metastatic melanoma (MM): preliminary results of a phase 1 study. Proc Am Soc Cancer Res; Washington (DC); 2006. p. 2883.
29. Davis ID, Redman BC, McArthur G, et al. Recombinant human Interleukin-21 (rIL-21), a new cytokine for immunotherapy: results of two phase 1 studies in patients with metastatic melanoma (MM) or renal cell carcinoma (RCC). 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; Prague; 2006. p. 265.
30. Lundsgaard D, Frederiksen KS, Skrumsager BK, Davis I, McArthur GA, Skak K. Interleukin-21: intravenous administration of interleukin-21 leads to immune activation in humans - preliminary results from a phase 1 trial. Federation of Clinical Immunology Societies (FOCIS); San Francisco; 2006. p. Sa.54.
31. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
32. Junghans RP, Waldmann TA. Metabolism of Tac (IL2Rα): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding. J Exp Med 1996;183:1587-602.
33. Davis ID, Morris L, Quirk J, et al. A pilot study of peripheral blood dendritic cells (PBDC) pulsed with NY-ESO-1 ISCOMATRIX® vaccine (ESO/IMX) in patients with treated cancer and minimal residual disease at high risk of relapse. Proc Am Soc Cancer Res; Anaheim (CA); 2005. p. 3466.